Changes in antipsychotic and antiparkinsonian medications should be undertaken with extreme caution due to the risk of Neuroleptic Malignant-Like Syndrome.
Requires extreme caution withdrawing antiparkinsonian agents from antipsychotic-treated patients; single case leaves open need for prospective validation.
This case report highlights the risk of development of Neuroleptic Malignant-Like Syndrome secondary to withdrawal of procyclidine with brief withdrawal of L-dopa and long-term typical antipsychotic depot. The patient responded to reintroduction of procyclidine, sedation and supportive treatment. The mechanism and management of NMS and NMLS is also reviewed. This case emphasises that any changes in antipsychotic and antiparkinsonian medications should be undertaken with extreme caution and patient should be closely monitored for development of NMLS after alteration in these medications.
No takes yet. Share an insight, caveat, or question.
Waqas et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: